Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Good health; any underlying chronic illness must be documented to be in stable condition~* Highly unlikely to conceive through 6 weeks after administration of the study vaccine~Exclusion Criteria:~* Prior administration of any pneumococcal vaccine~* History of invasive pneumococcal disease (IPD) \[positive blood culture, positive cerebrospinal fluid culture, or other sterile site) or known history of other culture-positive pneumococcal disease~* Known hypersensitivity to any vaccine component~* Known or suspected impairment of immune function~* Received systemic corticosteroids for \>=14 consecutive days and has not completed treatment \<=30 days prior to study entry, or received systemic corticosteroids exceeding physiologic replacement doses within 14 days prior to study vaccination~* Coagulation disorder contraindicating intramuscular vaccination~* Receives immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and treatments associated with organ or bone marrow transplantation, or autoimmune disease~* Received a blood transfusion or blood products, including immunoglobulins within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.~* Participated in another clinical study of an investigational product within 2 months before the beginning of or any time during the duration of the current clinical study~* Breast feeding~* User of recreational or illicit drugs or has had a recent history (within the last year) of drug or alcohol abuse or dependence

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- V114 Formulation A (Type: EXPERIMENTAL): Participants receive a single 0.5 mL intramuscular injection of V114 Formulation A on Day 1
- V114 Formulation B (Type: EXPERIMENTAL): Participants receive a single 0.5 mL intramuscular injection of V114 Formulation B on Day 1
- Prevnar 13® (Type: ACTIVE_COMPARATOR): Participants receive a single 0.5 mL intramuscular injection of Prevnar 13® on Day 1

Based on this trial design, predict the completion outcome and termination type (if applicable).